Targeting pd-l1/tgf- β, Bioinformatics bifunctional fusion protein has been approved by FDA
Bj-005 is a humanized anti programmed death ligand 1 (PD-L1) IgG1 monoclonal antibody and human transforming growth factor β (TGF- β) A recombinant bifunctional fusion protein fused from a part of the extracellular domain of receptor II, which can simultaneously target PD-L1 and TGF- β, It is used to treat cancer patients by targeting immune checkpoints and cytokine pathways that regulate tumor cell growth to inhibit tumor growth.